Actor Lee Jae-wook vows legal action against malicious rumors
Police raid striking doctors' homes, offices, after deadline passes on return-to-work order
Yoon touts improved Japan ties on Independence Movement Day as gateway to 'new world'
S. Korea, US voice 'deep concern' over NK's definition of S. Korea as 'hostile' country
S.Coups of Seventeen gets military exemption due to knee injury
Korean stocks benefit from Zuckerberg's Seoul visit
Most doctors refuse to end strike on last day of ultimatum
Vote on bill to probe first lady lays bare Democratic Party split
Address by President Yoon Suk Yeol on the 105th March 1st Independence Movement Day
Cooperation among N. Korea, Russia, China, Iran raises possibility of 'simultaneous conflicts': US general
Daewoong to initiate phase 3 trial of camostat in combination with remdesivirBy Lim Jeong-yeo
Published : Jan. 4, 2021 - 14:50
Foistar, which is administered orally in tablet form, uses camostat as its active ingredient and is hoped to reduce the viral load of COVID-19 in an infected person’s body.
In the beginning of the race for COVID-19 treatments, scientists believed that repurposing drugs such as Foistar would yield the fastest outcome, as the approval process would be truncated. With the drug’s safety for humans already established, the next step is to ascertain whether it is effective against COVID-19 as well as pancreatitis.
However, in a midterm report for a clinical phase 2a trial, the drug failed to yield a result with statistical significance when used on COVID-19 patients with mild symptoms. The company continues to develop the drug for COVID-19, saying that despite an unimpressive recovery speed, camostat had still cleared the virus from the subjects in the test group at a faster rate than those in the placebo group.
CEO Jeon Seng-ho of Daewoong Pharmaceutical said in a press interview that he envisions marketing Foistar as a COVID-19 treatment within January. Analyst Huh Hye-min of Kiwoom Securities predicted that should Daewoong succeed in its endeavors, this would reflect positively on investor sentiment.
In the phase 3 clinical trial, the final phase of testing before a drug is officially approved by the authorities, Daewoong will seek to find out if Foistar, together with remdesivir, can help severe COVID-19 patients.
Approximately 1,000 test subjects will be tested in the double-blind, randomized, placebo-controlled, multicenter phase 3 trial. It will be conducted by some 70 hospitals, including the National Medical Center.
By Lim Jeong-yeo (firstname.lastname@example.org)
Opposition leader retains ticket to his constituency
Car camping: How solo female campers enjoy outdoors
Tensions loom as doctors plan mass rally in deepening clash over med school quota